iMed Systems Ltd logo - click for high-res version

Emerade - the new adrenaline pen that follows UK Resuscitation Guidelines

2014-06-11

June 11, 2014, London, UK. Press Dispensary. A recent review* of adrenaline auto-injectors by the UK medical regulator MHRA included new recommendations on performance and dosage. In the wake of this, iMed Systems Ltd, a UK based pharmaceutical company, announces the launch of Emerade® - a new design of adrenaline auto-injector that follows the UK Resuscitation Council's guidelines for healthcare providers**.

More than 200,000 men, women and children in the UK live with the risk of suffering a fatal allergic reaction if exposed to a particular trigger. It may be certain foods such as peanuts or it could be a wasp sting. The condition is known as Anaphylaxis. For those at risk, avoiding these triggers can often become a dominant factor in managing their day to day life.  Unfortunately, avoidance is not always possible and accidental exposure can happen. In these cases the first line emergency treatment is a rapid injection of adrenaline, directly into the thigh muscle.

To maximise the likelihood of achieving the necessary depth of intra-muscular injection***, the new  Emerade® design features longer intra-muscular needles.

We have been asking manufacturers to supply auto injectors that have a larger dose and longer needles. We need to get the right dose to the right place
Dr. Richard Pumphrey

Dr. Richard Pumphrey****, the UK's leading specialist in the field of anaphylaxis fatalities, says: "We have been asking manufacturers to supply auto injectors that have a larger dose and longer needles. We need to get the right dose to the right place. In fact, this is exactly what the UK Resuscitation Council has been recommending for years."

Training patients and carers to safely use their auto-injectors is also a key challenge for healthcare providers.  Designing Emerade® to offer an intuitive experience has therefore been a key priority for the development team. The simplicity of its use can be seen in a short video on the Emerade® website. www.emerade.com/instruction-video

Adrenaline pens are much like insurance policies - thankfully, most are never needed. In order to reduce costs to the NHS, Emerade® is manufactured with a 30 month shelf-life.

Emerade® is now available on NHS prescription across the UK.

For more details and full prescribing information, please visit www.emerade.com.

- ends -

Notes for editors

Prescribing Information. Emerade® 150, 300 and 500 micrograms of adrenaline solution for injection in a pre-filled pen. Indications: For the emergency treatment of severe acute allergic reactions (anaphylaxis) triggered by allergens in foods, medicines, insect stings or bites, and other allergens as well as for exercise-induced or idiopathic anaphylaxis. Dosage: ADULTS AND ADOLESCENTS: The recommended dose is 300 to 500 micrograms. CHILDREN: Patients between 15 kg and 30 kg in weight: The usual dose is 150 micrograms. For intramuscular injection only. Emerade should only be injected into the anterolateral aspect of the thigh through clothing if necessary. A second injection with an additional Emerade injector may be administered after about 5 – 15 minutes if necessary. As Emerade is designed for emergency treatment, the patient should always seek immediate medical attention even if symptoms have disappeared. Contraindications: There are no absolute contraindications to the use of Emerade in an allergic shock. Precautions: Emerade must be administrated only into the anterolateral thigh. Patients should be advised not to inject Emerade into the gluteus maximus due to the risk of accidental injection into a vein. Accidental injection into the hands or feet can result in peripheral ischemia that may require treatment. Patients must be instructed in the proper use of Emerade. Use with caution in patients with heart diseases including angina pectoris, cardiac arrhythmia, cor pulmonale, obstructive cardiomyopathy and atherosclerosis. There is also a risk for adverse reactions after the administration of adrenaline to patients with hyperthyroidism, hypertension, phaeochromocytoma, glaucoma, severe renal impairment, prostate adenoma, hypercalcaemia, hypokalaemia, diabetes, and in elderly patients and pregnant women. The effects of adrenaline may be potentiated by tricyclic antidepressants and monoamine oxidase inhibitors. Adrenaline should be used in pregnancy only if the potential benefit justifies any potential risk to the foetus. Side effects: May include headache, palpitations, tachycardia, sweating, nausea and vomiting, respiratory difficultly, pallor, dizziness, nervousness and anxiety. Cardiac arrhythmias may follow administration of adrenaline. Overdoses of adrenaline may cause cerebral haemorrhage or arrhythmias. For a complete list of warnings and side effects, you should consult the Summary of Product Characteristics. Legal category: POM.  Price: Emerade 150 mcg £26.94, Emerade 300 mcg £26.94, Emerade 500 mcg £28.74.  Package and quantity: Emerade 150, 300 and 500 are available as single unit doses. Product licence number: Emerade 150, PL 42457/0001. Emerade 300, PL 42457/0002. Emerade 500, PL 42457/0003. Marketing authorisation holder: Namtall AB, Box 24005, SE-75024 Uppsala, Sweden.

References:

* http://bit.ly/mhrareview (MHRA review of adrenaline auto-injectors).

Recommendations of the independent expert panel advising the MHRA include:
 
- that the needle length for all AAIs should be reviewed by the manufacturers and increased, if necessary, to ensure that an intramuscular injection is delivered to a greater proportion of patients. (NB Emerade is fitted with needle lengths that follow the recommendation of the UK Resuscitation Council)
 
- that manufacturers be encouraged to develop a 500 μg strength AAI. (NB The Emerade range includes a 500 μg strength)

** http://bit.ly/1ku76Iw (Anaphylactic reactions - initial treatment)

*** http://bit.ly/1mQB6he (European Medicines Agency - adrenaline auto-injectors)

**** http://bit.ly/epipenlives (EAACI - Do 'EpiPens' Save Lives?)

Press contacts: London office
Alan Stern, iMed Systems Ltd
Tel: 07946 475 705
Email:
Site: www.emerade.com

Teesside Office
David Bowes
Tel: 07414 771 555
Email:

Image library: http://www.emerade.com/press/images

Media contacts

Alan Stern
Tel: 07946 475 705
Email:
Site: www.emerade.com

Teesside Office
David Bowes
Tel: 07414 771 555
Email:

Image library: http://www.emerade.com/press/images

Keywords/tags
adrenaline pen new compliancy improved dose longer adrenaline needles auto injector anaphylactic emergencies intra muscular injection

Permalink: http://bit.ly/emerade

Images for download
Click on any image to view or download in higher resolution.